{
    "id": "b83e23d2-7598-4a24-a2ff-dd522905cc04",
    "code": {
        "code": "34391-3",
        "codeSystem": "2.16.840.1.113883.6.1",
        "displayName": "HUMAN PRESCRIPTION DRUG LABEL"
    },
    "organization": "Baxter Healthcare Corporation",
    "effectiveTime": "20250221",
    "ingredients": [
        {
            "name": "VASOPRESSIN",
            "code": "Y4907O6MFD",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9937"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17996"
        },
        {
            "name": "SODIUM LACTATE",
            "code": "TU7HW0W0QT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_24996"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        }
    ],
    "indications": [
        {
            "text": "1 usage vasopressin sodium chloride injection indicated increase blood pressure adults vasodilatory shock remain hypotensive despite fluids catecholamines . vasopressin sodium chloride injection indicated increase blood pressure adults vasodilatory shock remain hypotensive despite fluids catecholamines . ( 1 )",
            "doid_id": null,
            "orphanet_entities": []
        }
    ],
    "contraindications": [
        {
            "text": "4 vasopressin sodium chloride injection contraindicated patients known allergy hypersensitivity 8-l-arginine vasopressin . \u2022 vasopressin sodium chloride injection contraindicated patients known allergy hypersensitivity 8-l-arginine vasopressin . ( 4 )",
            "doid_id": "http://purl.obolibrary.org/obo/DOID_1205",
            "orphanet_entities": []
        }
    ],
    "warningsAndPrecautions": "5 \u2022 worsen cardiac function ( 5.1 ) \u2022 reversible diabetes insipidus ( 5.2 ) 5.1 worsening cardiac function decrease cardiac index may observed vasopressin . 5.2 reversible diabetes insipidus patients may experience reversible diabetes insipidus , manifested development polyuria , dilute urine , hypernatremia , cessation treatment vasopressin . monitor serum electrolytes , fluid status urine output vasopressin discontinuation . patients may require readministration vasopressin desmopressin correct fluid electrolyte shifts .",
    "adverseReactions": "6 following associated vasopressin identified literature . reported voluntarily population uncertain size , possible estimate reliably frequency establish causal relationship exposure . bleeding/lymphatic system disorders : hemorrhagic shock , decreased platelets , intractable bleeding cardiac disorders : right heart failure , atrial fibrillation , bradycardia , myocardial ischemia gastrointestinal disorders : mesenteric ischemia hepatobiliary : increased bilirubin levels renal/urinary disorders : acute renal insufficiency vascular disorders : distal limb ischemia metabolic : hyponatremia skin : ischemic lesions postmarketing experience reversible diabetes insipidus [ ( 5.2 ) ] common include decreased cardiac output , bradycardia , tachyarrhythmias , hyponatremia ischemia ( coronary , mesenteric , skin , digital ) . ( 6 ) report suspected , contact baxter healthcare 1-866-888-2472 fda 1-800-fda-1088 www.fda.gov/medwatch .",
    "indications_original": "1 INDICATIONS AND USAGE Vasopressin in Sodium Chloride Injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. Vasopressin in Sodium Chloride Injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. ( 1 )",
    "contraindications_original": "4 CONTRAINDICATIONS Vasopressin in Sodium Chloride Injection is contraindicated in patients with a known allergy or hypersensitivity to 8-L-arginine vasopressin. \u2022 Vasopressin in Sodium Chloride Injection is contraindicated in patients with known allergy or hypersensitivity to 8-L-arginine vasopressin. ( 4 )",
    "warningsAndPrecautions_original": "5 WARNINGS AND PRECAUTIONS \u2022 Can worsen cardiac function ( 5.1 ) \u2022 Reversible diabetes insipidus ( 5.2 ) 5.1 Worsening Cardiac Function A decrease in cardiac index may be observed with the use of vasopressin. 5.2 Reversible Diabetes Insipidus Patients may experience reversible diabetes insipidus, manifested by the development of polyuria, a dilute urine, and hypernatremia, after cessation of treatment with vasopressin. Monitor serum electrolytes, fluid status and urine output after vasopressin discontinuation. Some patients may require readministration of vasopressin or administration of desmopressin to correct fluid and electrolyte shifts.",
    "adverseReactions_original": "6 ADVERSE REACTIONS The following adverse reactions associated with the use of vasopressin were identified in the literature.  Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to estimate reliably their frequency or establish a causal relationship to drug exposure. Bleeding/lymphatic system disorders: Hemorrhagic shock, decreased platelets, intractable bleeding Cardiac disorders: Right heart failure, atrial fibrillation, bradycardia, myocardial ischemia Gastrointestinal disorders: Mesenteric ischemia Hepatobiliary: Increased bilirubin levels Renal/urinary disorders: Acute renal insufficiency Vascular disorders: Distal limb ischemia Metabolic: Hyponatremia Skin: Ischemic lesions Postmarketing Experience Reversible diabetes insipidus [ see Warnings and Precautions (5.2) ] The most common adverse reactions include decreased cardiac output, bradycardia, tachyarrhythmias, hyponatremia and ischemia (coronary, mesenteric, skin, digital). ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Baxter Healthcare at 1-866-888-2472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.",
    "drug": [
        {
            "name": "Vasopressin in 0.9% Sodium Chloride",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9937"
        }
    ]
}